presentation of wouter de maeseneire
TRANSCRIPT
![Page 1: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/1.jpg)
SOME PHARMA FINANCIALS
PROF. DR. WOUTER DE MAESENEIRE
![Page 2: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/2.jpg)
DISCLAIMER
I am not a pharma/healthcare expert
But I did quite some work for student in-company projects or customized trainings for
Pfizer, J&J (Janssen), Arseus, Capsugel, UCB, Boehringher-Inghelheim,…
IRC MFM last year: UCB
I wrote a case on BigPharma vs Small BiotechFSA
I’ll give a broad overview of some of the issues
![Page 3: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/3.jpg)
© Vlerick Business School3
![Page 4: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/4.jpg)
© Vlerick Business School
PROFIT AND LOSS ACCOUNT/INCOME STATEMENT
4
![Page 5: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/5.jpg)
© Vlerick Business School
APPLE: PROFIT AND LOSS ACCOUNT (P&L)
5
![Page 6: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/6.jpg)
© Vlerick Business School
DO YOU KNOW…
6
![Page 7: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/7.jpg)
© Vlerick Business School
AN UNFORESEEN OUTCOME…
7
![Page 8: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/8.jpg)
© Vlerick Business School
LIPITOR
Peak sales
Cumulative sales (1996-2012)
8
![Page 9: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/9.jpg)
© Vlerick Business School
PFIZER: PROFIT AND LOSS ACCOUNT (P&L)
9
![Page 10: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/10.jpg)
![Page 11: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/11.jpg)
![Page 12: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/12.jpg)
12
![Page 13: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/13.jpg)
13
![Page 14: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/14.jpg)
14
![Page 15: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/15.jpg)
15
![Page 16: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/16.jpg)
16
![Page 17: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/17.jpg)
17
![Page 18: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/18.jpg)
18
![Page 19: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/19.jpg)
© Vlerick Business School
GALAPAGOS
19
![Page 20: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/20.jpg)
© Vlerick Business School
GALAPAGOS: P&L
20
![Page 21: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/21.jpg)
© Vlerick Business School21
![Page 22: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/22.jpg)
© Vlerick Business School
GALAPAGOS: ASSETS
22
![Page 23: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/23.jpg)
© Vlerick Business School
GALAPAGOS: EQUITY AND LIABILITIES
23
![Page 24: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/24.jpg)
© Vlerick Business School
GALAPAGOS: CASH FLOW STATEMENT
24
![Page 25: Presentation of Wouter De Maeseneire](https://reader031.vdocuments.us/reader031/viewer/2022032021/55a54d231a28ab48708b461c/html5/thumbnails/25.jpg)
© Vlerick Business School
A LOT OF BIG PHARMA & SMALL BIOTECHDEALS
M&A, alliances, milestone payments, co-development, licencsing out,…
Clear complementarities
25